Lung Cancer | Tumor

Less Is More in Lung Cancer Treatment

June 17th 2021, 1:00pm


Novel combo regimen reduces number of toxic treatments in patients with NSCLC.

Educating Patients About Biomarker Testing

June 16th 2021, 3:21pm


Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.

The Emerging Role of Liquid Biopsies

June 16th 2021, 3:15pm


Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

Best Practices When Testing With Comprehensive Genomic Profiling

June 9th 2021, 2:45pm


Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.

Comprehensive Genomic Profiling in Lung and Thyroid Cancer

June 9th 2021, 2:35pm


Drs Benjamin Levy and Lori J. Wirth describe how they currently utilize comprehensive genomic profiling to manage patients with non–small cell lung cancer or thyroid cancer.

Opdivo-Yervoy Combination Could Benefit Patients with Non-Small Cell Lung Cancer

June 8th 2021, 1:00pm


Combination of Opdivo and Yervoy had improved efficacy and durable response after four years in patients with advanced non-small cell lung cancer.

Novel Tyrosine Kinase Inhibitor Shows Promise for Metastatic Non-Small Cell Lung Cancer With Specific Genetic Mutation

June 8th 2021, 12:00pm


Mobocertinib showed clinically meaningful benefits in patients with EGFR exon 20 insertion–positive metastatic non-small cell lung cancer with a manageable safety profile.

Alecensa Fails to Improve Survival in Lung Cancer Subset

June 7th 2021, 8:00pm


In a final analysis of a study examining the effectiveness of Alecensa compared to Xalkori in patients with non-small cell lung cancer, the Alecensa-treated group did not achieve better survival outcomes.

Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer

June 7th 2021, 1:00pm


The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Aumolertinib Improves Survival in Advanced Non-Small Cell Lung Cancer

June 7th 2021, 12:00pm


Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.